BFRI (Biofrontera) FFO


BFRI Biofrontera Inc BFRI
44 GF Score
Price $0.99
GF Value $0.54
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Biofrontera FFO?

FFO (Funds from operations) only applies to REITs.

BFRI
44GF Score
Biofrontera Inc BFRI
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Biofrontera (BFRI) Overvalued in 2026?

Based on GuruFocus' analysis, Biofrontera stock appears to be overvalued. The current stock price of $0.99 is trading 84.2% above its estimated GF Value™ of $0.54. GuruFocus considers Biofrontera to be Significantly Overvalued.

Key valuation signals for BFRI:

  • FFO:
  • GF Value™: $0.54 vs. price of $0.99 (84.2% above fair value)
  • GF Score™: 44/100 with 4 warning signs

No single metric tells the full story. See the BFRI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biofrontera Business Description

Address 660 Main Street, 1st Floor, Woburn, MA, USA, 01801
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. The company's revenues are derived from within the United States and, therefore, no other geographical segments.
44GF Score

Get the complete analysis for BFRI

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.99
Price
$0.54
GF Value